Tony Johnson, Goldfinch Bio CEO (Goldfinch via YouTube)

Kid­ney dis­ease drug­mak­er Goldfinch Bio shuts down

Goldfinch Bio, at­tempt­ing to make treat­ments for kid­ney dis­eases and di­a­bet­ic nephropa­thy, is shut­ting down.

Pres­i­dent and CEO Tony John­son con­firmed to End­points News Fri­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.